Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary Officer
Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the appointment of Philippe Brianceau, DVM, as chief veterinary officer, effective immediately.
Philippe Brianceau brings more than 20 years of animal health experience following the completion of his doctorate in veterinary medicine from the Toulouse Veterinary School in France. Most recently, Brianceau served as director of global pharmaceutical project development at Merck Animal Health, where he led new product development teams for both companion and livestock animals. He also served as director of US clinical research for Merck Animal Health for four years, during which time he oversaw field study operations and clinical development plans for new animal drugs. Brianceau began his career in the pharmaceutical industry in 2001 with Schering Plough Animal Health, followed by Intervet, where he remained through the organization’s acquisition by Merck Pharmaceuticals in 2009.
“The addition of Dr. Brianceau to the Jaguar management team comes at a pivotal time for the Company, as we recently announced additional positive findings from our SB-300 proof-of-concept study for equine gastric ulcer syndrome,” said Lisa Conte, Jaguar’s president and CEO. “Philippe’s research and development experience at Merck Animal Health in conjunction with his past experience in equine internal medicine and surgery will provide unparalleled insight into the equine and companion animal markets-two of our core focus areas. We are confident in his ability to lead our veterinary team as we pursue regulatory approvals and initiate further clinical trials and research activities.”
Philippe Brianceau stated, “I am very excited to be named chief veterinary officer of an emerging animal health company committed to developing innovative, first-in-class products for both companion and production animals. I look forward to leveraging my experience in pharmaceutical product development and my background in veterinary medicine and surgery to help Jaguar bring the multiple products in its pipeline to market.”